Ignacio
Melero Bermejo
Catedrático de Universidad
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (5)
2021
-
An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177
-
OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors
Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472
2018
-
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
Nature Communications, Vol. 9, Núm. 1
2012
-
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies
OncoImmunology, Vol. 1, Núm. 8, pp. 1344-1354
2011
-
New trends in immunotherapy
Inmunologia